JPRN-UMIN000012535已完成2 期
Multicenter phase II study of CapeOX (XELOX) with stop-and-go strategy as adjuvant chemotherapy in high-risk Stage II or Stage III colon and rectal cancer - COACH Trial (CCOG 1302)
Chubu Clinical Oncology Group0 个研究点目标入组 200 人开始时间: 2013年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Appendix cancer or anal cancer (2)Distal extent of tumor must be in the Rb (3)Multiple malignacies to be treated (4)Ileus, bowel obstruction or uncontrolled peptic ulcer. (5)Uncontrolled severe complications(DM, hypertension, diarrhea, et al.) (6)Massive pleural effusion or ascites that required drainage. (7) Patient with symptomatic cardiovascular disease or asymptomatic disease but has been treated (>=Grade 2 according to NCI-CTCAE ver.4). History of myocardial infarction within a year. (8) A history of allergy to 5-FU, platina, or Known dihydropyrimidine dehydrogenase (DPD) deficiency. (9)Severe neuropathy (10)With interstitial lung disease or pulmonary fibrosis (11)Continuous systemic steroid therapy (oral or intravenous administration). (12)A history and/or current evidence of significant neurological and/or mental illness. (13)Pregnant (14)Without intention to contraception (15)Prior chemotherapy including Oxaliplatin or Capecitabin (16)Not appropriate for the study at the physician's assessment.
研究者
相似试验
已完成
2 期
Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancerColorectal cancerJPRN-UMIN000007547Chubu Clinical Oncology Group (CCOG)100
已完成
2 期
Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancercolorectal cancerJPRN-UMIN000003500Epidemiological and Clinical Research Information Network (ECRIN)35
已完成
2 期
A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.nresectable advanced/recurrent colorectal cancerJPRN-UMIN000005060Fukuoka University Hospital100
已完成
2 期
Multicenter Phese II Study of Optimal-XELOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral capecitabin plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerColorectal cancerJPRN-UMIN000006478Chubu Clinical Oncology Group (CCOG)50
招募中
2 期
Phase 2 study of CapeOX plus nivolumab for patients with early relapsed gastric cancerGastric CancerJPRN-jRCTs031220572Arai Hiroyuki92